Institute of Nanoscience and Nanotechnology, Kafrelsheikh University, 33516 Kafrelsheikh, Egypt.
CNR NANOTEC-Istituto di Nanotecnologia, Via Monteroni, Lecce 73100, Italy.
Int J Biol Macromol. 2021 Jul 1;182:1150-1160. doi: 10.1016/j.ijbiomac.2021.03.189. Epub 2021 Apr 15.
In the current study, the treatment efficacy of ECHCAH was evaluated in vitro studies using cell viability and flow cytometry in human TNBCs. The results here showed significant gradual reduction in growth of TNBCs (MDA-231cell lines) after their exposure to serial concentrations for hydrogel assembly (5 μg/mL to 25 μg/mL) for 24 and 48 h, representing (86 ± 1% to 45 ± 1.5% p < 0.001) and (79 ± 1.5% to 35 ± 2.5% p < 0.001) respectively. The flow cytometry showed significant increase in the present of late apoptotic and necrotic cells (64% ± 1.2 and 27% ± 0.3 p < 0.001) after 48 h incubation compared to untreated cells (1.13% ± 0.3 and 4% ± 0.2 p < 0.001) respectively. It can be summarized that ECHCA inside targeted hydrogel assemblies can inhibit proliferation of cancer cells.
在本研究中，使用细胞活力和流式细胞术在体外研究中评估了 ECHCAH 的治疗效果，用于人类三阴性乳腺癌（TNBC）。结果显示，在暴露于水凝胶组装的连续浓度（5 μg/mL 至 25 μg/mL）24 和 48 小时后，TNBC（MDA-231 细胞系）的生长显著逐渐减少，分别为（86 ± 1%至 45 ± 1.5%，p < 0.001）和（79 ± 1.5%至 35 ± 2.5%，p < 0.001）。流式细胞术显示，与未处理的细胞（分别为 1.13% ± 0.3 和 4% ± 0.2，p < 0.001）相比，在孵育 48 小时后，晚期凋亡和坏死细胞的存在显著增加（分别为 64% ± 1.2 和 27% ± 0.3，p < 0.001）。可以总结得出，ECHCA 存在于靶向水凝胶组装物中可以抑制癌细胞的增殖。
